2018 American Society of Clinical Oncology Annual Meeting*

ASCO 2018 Program Image
Download All
June 1-5, 2018; Chicago, Illinois
CCO’s expert faculty review and share their expert perspectives on key findings in hematologic malignancies presented at the 2018 ASCO annual meeting.
John M. Burke, MD
Elias Jabbour, MD
Shaji K. Kumar, MD

Hematologic Malignancies

Slidesets Durability of Response to Axicabtagene Ciloleucel in Patients With Refractory DLBCL: Long-term Follow-up of Phase II ZUMA-1 Trial
Slidesets Phase I Study of Ivosidenib, an Investigational IDH Inhibitor, in Relapsed/Refractory IDH1-Mutated Acute Myeloid Leukemia
Slidesets Study 1503: Moxetumomab Pasudotox in Heavily Pretreated Relapsed/Refractory Hairy Cell Leukemia
Slidesets Phase Ib Study of Venetoclax With Decitabine or Azacitidine in Elderly Patients With Untreated Acute Myeloid Leukemia
Slidesets Long-term Survival With Blinatumomab and Allogeneic HSCT in B-Cell Precursor Acute Lymphoblastic Leukemia
Slidesets RELEVANCE: Phase III Study of Lenalidomide + Rituximab vs Chemotherapy + Rituximab in Untreated Follicular Lymphoma
Slidesets ACE-WM-001: Phase II Study of Acalabrutinib in Patients With Untreated or Relapsed/Refractory Waldenström Macroglobulinemia
Slidesets Phase II CAPTIVATE: First-line Ibrutinib + Venetoclax in Chronic Lymphocytic Leukemia (Interim Analysis)
Slidesets A.R.R.O.W. Phase III Trial of Once- vs Twice-Weekly Carfilzomib + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Slidesets OPTIMISMM: Phase III Trial of Pomalidomide, Bortezomib, Low-Dose Dexamethasone vs Bortezomib, Low-Dose Dexamethasone Alone in Lenalidomide-Exposed RRMM
Slidesets Daratumumab, Carfilzomib, and Dexamethasone in Lenalidomide-Refractory Relapsed Myeloma (MMY1001 Subgroup Analysis)
Slidesets iNNOVATE (PCYC-1127): Phase III Study of Ibrutinib/Rituximab in Waldenström Macroglobulinemia
Slidesets A Phase II Trial of Venetoclax, Carfilzomib, and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Slidesets Anti-BCMA CAR T-Cell Therapy bb2121 in R/R Multiple Myeloma: Updated Phase I Dose-Escalation and Dose-Expansion Results
Slidesets SWOG S1304: Low- vs High-Dose Carfilzomib + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Review expert insights on key presentations on hematologic malignancies from the 2018 ASCO annual meeting.

John M. Burke, MD Elias Jabbour, MD Shaji K. Kumar, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 28, 2018 Expired: No longer available for credit
Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue